Perrigo Company has launched its AB therapeutic equivalent testosterone gel 1.0 per cent. The Food and Drug Administration (FDA) concluded previously that Perrigo's testosterone product is therapeutically equivalent to AbbVie's AndroGel 1.0 per cent and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as AndroGel 1.0 per cent when used under the conditions specified in the labelling.
Androgel 1.0 per cent (testosterone gel 1.0 per cent) is indicated to treat adult males who have low or no testosterone. Annual sales were greater than $300 million, as measured by Symphony Health Solutions.
Perrigo's chairman, president and CEO Joseph C. Papa stated, "We are very pleased to launch an AB equivalent testosterone 1.0 per cent product. It occurred as a result of a strong effort by our research and development and the entire Rx team. This highlights our commitment to bringing quality affordable healthcare products to the market."
From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri. The Company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America.